{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:10:09Z","timestamp":1786975809373,"version":"build-2736575974"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Despite established treatment guidelines and strong therapeutic benefit, hydroxyurea remains underused among patients with sickle cell disease.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the change in self-reported hydroxyurea use (ie, taking the medication at all) and adherence (ie, the number of days taken per week) over time and to examine factors associated with the trajectory of hydroxyurea use and adherence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Data were collected through the Sickle Cell Disease Implementation Consortium, a longitudinal, multicenter, observational cohort study that recruited patients from 8 centers across the US. Data collection occurred from 2017 to 2022, and analyses were performed from January to October 2025. Data were collected via self-report survey at baseline and 3 follow-up surveys distributed yearly. Patients with sickle cell disease of all genotypes between the ages of 15 and 45 years were included.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Sickle cell disease.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Hydroxyurea use was analyzed as a binary variable according to whether the participant was currently taking hydroxyurea. Among those taking hydroxyurea, adherence was analyzed as a continuous variable according to the number of days hydroxyurea was taken within the past week. Continuous variables were\n z<\/jats:italic>\n scored to ensure model convergence, and odds ratios (ORs) are reported.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 2514 eligible participants, surveys were completed by 2207 participants at baseline, 1802 at follow-up 1, 1281 at follow-up 2, and 783 at follow-up 3. Of 2207 participants at baseline, 1265 (57.3%) were female, with a mean (SD) age of 28.06 (7.86) years. Overall rates of hydroxyurea use remained stable throughout the study (1089 of 2207 patients [49.3%] at baseline, 887 of 1802 patients [48.7%] at first follow-up, 609 of 1281 patients [47.5%] at second follow-up, and 378 of 783 patients [48.3%] at third follow-up). However, patients with HbSS\/SB\n 0<\/jats:sup>\n -thalassemia showed declining use (790 of 1550 patients [50.9%] at baseline, 627 of 1276 patients [49.1%] at first follow-up, 429 of 905 patients [47.4%] at second follow-up, and 282 of 586 patients [48.1%] at third follow-up), whereas patients with other genotypes showed increasing use (299 of 657 patients [45.5%] at baseline, 250 of 526 patients [47.5%] at first follow-up, 168 of 352 patients [47.7%] at second follow-up, and 90 of 186 patients [48.4%] at third follow-up) across time points (OR, 0.76; 95% CI, 0.63 to 0.91;\n P<\/jats:italic>\n \u2009=\u2009.004). Hydroxyurea adherence declined over time (\u22120.19 days\/week\/year; 95% CI, \u22120.24 to \u22120.14 days\/week\/year;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Executive difficulties were associated with worse adherence across time points (\u22120.17 days\/week\/year; 95% CI, \u22120.26 to \u22120.08 days\/week\/year;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this cohort study of patients with sickle cell disease, declining use of hydroxyurea among patients with HbSS\/SB\n 0<\/jats:sup>\n -thalassemia genotypes raises important concerns about ongoing disease management. Adherence to hydroxyurea is negatively associated with cognitive factors that may be addressed through interventions targeting self-monitoring and\/or behavioral activation.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.11257","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:30:24Z","timestamp":1778081424000},"page":"e2611257","source":"Crossref","is-referenced-by-count":1,"title":["Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease"],"prefix":"10.1001","volume":"9","author":[{"given":"Andrew M.","family":"Heitzer","sequence":"first","affiliation":[{"name":"Department of Psychology and Biobehavioral Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Wooten","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Treadwell","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology, University of California San Francisco, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Washington University in St Louis, St Louis, Missouri"},{"name":"Department of Medicine, Washington University in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R.","family":"Gordeuk","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Illinois at Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"McCuskee","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siera","family":"Gollan","sequence":"additional","affiliation":[{"name":"Center for Blood Disorders, Augusta University, Augusta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Longoria","sequence":"additional","affiliation":[{"name":"Department of Psychology and Biobehavioral Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane S.","family":"Hankins","sequence":"additional","affiliation":[{"name":"Department of Hematology, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"},{"name":"Department of Global Pediatric Medicine, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Sickle Cell Disease Implementation Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"16","key":"zoi260341r1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease.","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi260341r2","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"9778","key":"zoi260341r3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"zoi260341r4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400402","article-title":"Hydroxyurea for children and adults with hemoglobin SC disease.","volume":"4","author":"Dei-Adomakoh","year":"2025","journal-title":"NEJM Evid"},{"issue":"16","key":"zoi260341r5","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1001\/jama.2015.3075","article-title":"Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.","volume":"313","author":"Stettler","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"zoi260341r6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajh.20703","article-title":"Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.","volume":"81","author":"Lanzkron","year":"2006","journal-title":"Am J Hematol"},{"issue":"9","key":"zoi260341r7","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/pds.4860","article-title":"National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.","volume":"28","author":"Su","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi260341r8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1542\/peds.2014-0177","article-title":"Medication adherence among pediatric patients with sickle cell disease: a systematic review.","volume":"134","author":"Walsh","year":"2014","journal-title":"Pediatrics"},{"issue":"10","key":"zoi260341r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28971","article-title":"Hydroxyurea use after transitions of care among young adults with sickle cell disease and Tennessee Medicaid insurance.","volume":"4","author":"Mathias","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260341r10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.","volume":"86","author":"Candrilli","year":"2011","journal-title":"Am J Hematol"},{"issue":"9","key":"zoi260341r11","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s11606-021-06648-1","article-title":"An adaptable framework for factors contributing to medication adherence: results from a systematic review of 102 conceptual frameworks.","volume":"36","author":"Peh","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi260341r12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s40615-019-00625-5","article-title":"The role of patient-physician communication on the use of hydroxyurea in adult patients with sickle cell disease.","volume":"6","author":"Jabour","year":"2019","journal-title":"J Racial Ethn Health Disparities"},{"issue":"5","key":"zoi260341r13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/bjh.19099","article-title":"Provider prescription of hydroxyurea in youth and adults with sickle cell disease: a review of prescription barriers and facilitators.","volume":"203","author":"Pizzo","year":"2023","journal-title":"Br J Haematol"},{"issue":"18","key":"zoi260341r14","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/bloodadvances.2020001701","article-title":"Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.","volume":"4","author":"Hodges","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"zoi260341r15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jpeds.2009.09.044","article-title":"Adherence to hydroxyurea therapy in children with sickle cell anemia.","volume":"156","author":"Thornburg","year":"2010","journal-title":"J Pediatr"},{"issue":"1","key":"zoi260341r16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3285","article-title":"Hydroxyurea use for sickle cell disease among Medicaid-enrolled children.","volume":"144","author":"Brousseau","year":"2019","journal-title":"Pediatrics"},{"issue":"1","key":"zoi260341r17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/07853890.2022.2044509","article-title":"Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.","volume":"54","author":"Reddy","year":"2022","journal-title":"Ann Med"},{"issue":"1","key":"zoi260341r18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.26765","article-title":"Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.","volume":"98","author":"Kang","year":"2023","journal-title":"Am J Hematol"},{"key":"zoi260341r19","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.921432","article-title":"Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative.","volume":"13","author":"Treadwell","year":"2022","journal-title":"Front Genet"},{"key":"zoi260341r20","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1182\/blood-2021-149902","article-title":"Relationship of hydroxyurea adherence to depression and fatigue among children and adolescents with sickle cell disease: a longitudinal cohort study.","volume":"138","author":"Badawy","year":"2021","journal-title":"Blood"},{"issue":"3","key":"zoi260341r21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management.","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur J Haematol"},{"key":"zoi260341r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134445","article-title":"Neuropathic pain in individuals with sickle cell disease.","volume":"714","author":"Sharma","year":"2020","journal-title":"Neurosci Lett"},{"issue":"2","key":"zoi260341r23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.17687","article-title":"Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.","volume":"195","author":"Heitzer","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"zoi260341r24","doi-asserted-by":"publisher","first-page":"E391","DOI":"10.1002\/ajh.25282","article-title":"The sickle cell disease implementation consortium: translating evidence-based guidelines into practice for sickle cell disease.","volume":"93","author":"DiMartino","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"zoi260341r25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ajh.25880","article-title":"Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: report from the sickle cell disease implementation consortium.","volume":"95","author":"Knisely","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"zoi260341r26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10903-020-01102-6","article-title":"Effective recruitment strategies for a sickle cell patient registry across sites from the Sickle Cell Disease Implementation Consortium (SCDIC).","volume":"23","author":"Masese","year":"2021","journal-title":"J Immigr Minor Health"},{"issue":"1","key":"zoi260341r27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-020-01457-x","article-title":"Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.","volume":"15","author":"Glassberg","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"zoi260341r28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0738-3991(98)00107-4","article-title":"The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence.","volume":"37","author":"Svarstad","year":"1999","journal-title":"Patient Educ Couns"},{"issue":"11","key":"zoi260341r29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/ajh.26315","article-title":"Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.","volume":"96","author":"Longoria","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"zoi260341r30","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjh.19881","article-title":"Depression, sleep and pain affect instrumental activities of daily living through cognitive functioning in adults with sickle cell disease: report from the Sickle Cell Disease Implementation Consortium.","volume":"206","author":"Longoria","year":"2025","journal-title":"Br J Haematol"},{"issue":"23","key":"zoi260341r32","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology.","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"zoi260341r33","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/AJP.0000000000000054","article-title":"Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research.","volume":"30","author":"Treadwell","year":"2014","journal-title":"Clin J Pain"},{"issue":"5","key":"zoi260341r34","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000260537.45076.74","article-title":"Developing the Patient-Reported Outcomes Measurement Information System (PROMIS).","volume":"45","author":"Ader","year":"2007","journal-title":"Med Care"},{"key":"zoi260341r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"zoi260341r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: tests in linear mixed effects models.","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi260341r38","first-page":"1","article-title":"lavaan: An R package for structural equation modeling.","volume":"48","author":"Rosseel","year":"2012","journal-title":"J Stat Softw"},{"issue":"5","key":"zoi260341r39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/phar.2793","article-title":"Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: current evidence and knowledge gaps.","volume":"43","author":"Dong","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"4","key":"zoi260341r40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes.","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"zoi260341r41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1365-2214.2011.01282.x","article-title":"A social-ecological model of readiness for transition to adult-oriented care for adolescents and young adults with chronic health conditions.","volume":"37","author":"Schwartz","year":"2011","journal-title":"Child Care Health Dev"},{"issue":"2","key":"zoi260341r42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/PSY.0b013e31815ff5c5","article-title":"Depression and anxiety in adults with sickle cell disease: the PiSCES project.","volume":"70","author":"Levenson","year":"2008","journal-title":"Psychosom Med"},{"issue":"8","key":"zoi260341r43","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/jpepsy\/jsz031","article-title":"Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: a meta-analysis.","volume":"44","author":"Prussien","year":"2019","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"zoi260341r44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s44247-024-00138-0","article-title":"Factors influencing engagement with adherence-enhancing mobile health app in sickle cell disease.","volume":"2","author":"Abrams","year":"2024","journal-title":"BMC Digit Health"},{"key":"zoi260341r45","doi-asserted-by":"publisher","DOI":"10.3389\/frhs.2022.1024541","article-title":"Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.","volume":"2","author":"Hankins","year":"2023","journal-title":"Front Health Serv"},{"issue":"5","key":"zoi260341r46","doi-asserted-by":"publisher","DOI":"10.2196\/14884","article-title":"Development of the InCharge health mobile app to improve adherence to hydroxyurea in patients with sickle cell disease: user-centered design approach.","volume":"8","author":"Alberts","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"issue":"7","key":"zoi260341r47","doi-asserted-by":"publisher","DOI":"10.2196\/10940","article-title":"Patient-centered eHealth interventions for children, adolescents, and adults with sickle cell disease: systematic review.","volume":"20","author":"Badawy","year":"2018","journal-title":"J Med Internet Res"},{"issue":"4","key":"zoi260341r48","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30878","article-title":"Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.","volume":"71","author":"Green","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"zoi260341r49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/jpepsy\/jsaa031","article-title":"A systematic review of medication adherence interventions in pediatric sickle cell disease.","volume":"45","author":"Shih","year":"2020","journal-title":"J Pediatr Psychol"},{"issue":"9","key":"zoi260341r51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.nurpra.2014.07.033","article-title":"Depression, self-efficacy, and adherence in patients with type 2 diabetes.","volume":"10","author":"Adam","year":"2014","journal-title":"J Nurse Pract"},{"issue":"8","key":"zoi260341r52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/1357633X20955122","article-title":"Effectiveness of theory-based digital self-management interventions for improving depression, anxiety, fatigue and self-efficacy in people with neurological disorders: a systematic review and meta-analysis.","volume":"28","author":"Lau","year":"2022","journal-title":"J Telemed Telecare"},{"issue":"1","key":"zoi260341r53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1037\/a0038889","article-title":"A critique of the cross-lagged panel model.","volume":"20","author":"Hamaker","year":"2015","journal-title":"Psychol Methods"},{"key":"zoi260341r50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4419-6868-5_5","volume-title":"Self-Efficacy, Adaptation, and Adjustment: Theory, Research, and Application","author":"Maddux","year":"1995"},{"key":"zoi260341r31","unstructured":"HealthMeasures. HealthMeasures: transforming how health is measured. March 23, 2023. Accessed May 1, 2024. https:\/\/www.healthmeasures.net"},{"key":"zoi260341r35","unstructured":"R Foundation for Statistical Computing. R: A language and environment for statistical computing. 2022. Accessed March 25, 2026. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848673\/heitzer_2026_oi_260341_1777494527.90171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:30:34Z","timestamp":1778081434000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11257","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}